# Danaher Corporation (DHR) stock analysis and sentiment

Canonical page: https://synoptiv.com/stock/DHR
Methodology: https://synoptiv.com/methodology
Author: Synoptiv Research Engine

Last analyzed: Aug 23, 2026

Danaher Corporation (DHR) last closed at $218.85, in the upper half of its 52-week range of $160.93–$242.80. Composite market sentiment across 1 analysis is positive (+28 on a −100 to +100 scale), as of Aug 23, 2026.

## What the data says

Danaher closed at $218.85, roughly 36% above its 52-week low of $160.93 and about 10% below the $242.80 high. That places the stock in the upper third of its yearly range, but the range itself is wide — a spread of more than $80, or about half the low — so shares have covered a lot of ground over the past year rather than settling into a narrow band.

At a $153.8 billion market capitalization, the stock trades at about 39 times trailing earnings and roughly 24 times forward estimates. That gap between the two multiples reflects expectations of higher earnings ahead; on the trailing figure alone, the market is paying a premium to current profits. Price to book sits near 2.9. The underlying business converts about 15.9% of revenue into profit, with revenue growing 5.5%, and it returns a modest 0.73% dividend yield. A beta of 0.80 means the shares have historically moved less than the broader market, both on the way up and on the way down.

Recent headlines split between the company and its industry. Most items are third-party market-sizing reports on the fields Danaher operates in — biochemistry analyzers, molecular biology reagents, spatial genomics, laboratory equipment services — which mention the sector rather than the company's own results. The company-specific coverage from late June and July centers on a decline in the share price this year and on the Masimo acquisition, alongside sector news such as Merck KGaA's cash offer for Bio-Techne. Notably, none of the recent flow concerns earnings releases or company guidance.

## About Danaher Corporation

Danaher Corporation designs, manufactures, and markets products and services for biotechnology, life sciences, and diagnostics customers in the United States, China, and other markets worldwide. It reports in three segments. Biotechnology supplies the tools used to develop and manufacture biologic therapeutics, including cell line and cell culture media development services, process liquids and buffers, chromatography resins, filtration technologies, aseptic fill-finish, single-use hardware and consumables, and reagents and membranes for diagnostic and assay development. Life Sciences covers research instrumentation and materials — mass spectrometers, flow cytometry, genomics and lab automation systems, centrifuges, microscopes, antibodies and reagents, and custom nucleic acid and plasmid DNA production — sold under brands including Abcam, Aldevron, Beckman Coulter, IDT, Leica Microsystems, Molecular Devices, Pall, Phenomenex, and SCIEX. Diagnostics provides clinical instruments, consumables, software, and services used by hospitals, physicians' offices, reference laboratories, and critical care settings.

The company was incorporated in 1969 as Diversified Mortgage Investors and adopted the Danaher name in 1984. It is headquartered in Washington, D.C.

## Company profile

- Symbol: DHR
- Exchange: NYSE
- Security type: Stock
- Sector: Healthcare
- Industry: Diagnostics & Research
- Composite sentiment: positive (28 on a -100 to +100 scale)

## Key statistics

| Metric | Value |
| --- | ---: |
| Market capitalization | $153.85B |
| Enterprise value | $177.37B |
| Trailing P/E | 39.08 |
| Forward P/E | 23.54 |
| Price to book | 2.93 |
| Price to sales | 6.13 |
| Dividend yield | 0.73% |
| Beta | 0.8 |
| Net margin | 15.95% |
| Revenue growth | 5.50% |
| Earnings growth | 59.70% |
| 52-week high | $242.80 |
| 52-week low | $160.93 |
| Average volume | 4.9M |

## Related stocks

- [TMO](https://synoptiv.com/stock/TMO)
- [A](https://synoptiv.com/stock/A)
- [IQV](https://synoptiv.com/stock/IQV)
- [WAT](https://synoptiv.com/stock/WAT)
- [ILMN](https://synoptiv.com/stock/ILMN)
- [MTD](https://synoptiv.com/stock/MTD)
- [WST](https://synoptiv.com/stock/WST)
- [MEDP](https://synoptiv.com/stock/MEDP)
- [CRL](https://synoptiv.com/stock/CRL)
- [TEM](https://synoptiv.com/stock/TEM)
- [RVTY](https://synoptiv.com/stock/RVTY)

## Recent news

- [Is Bio-Rad a Buy as Digital PCR Growth Meets a Premium Valuation?](https://finance.yahoo.com/markets/stocks/articles/bio-rad-buy-digital-pcr-143100394.html) — Aug 21, 2026
- [Danaher (DHR) Jumped, But What Is Drawing Fresh Attention Now?](https://finance.yahoo.com/markets/stocks/articles/danaher-dhr-jumped-drawing-fresh-042832698.html) — Aug 20, 2026
- [Danaher (DHR) Stock Looks Fairly Valued On Its 23% Five Year Slide](https://finance.yahoo.com/markets/stocks/articles/danaher-dhr-stock-looks-fairly-021415855.html) — Aug 20, 2026
- [Molecular Diagnostics Market to Grow from USD 19.48 Billion in 2025 to USD 30.74 Billion by 2030, at a CAGR of 9.6% - MarketsandMarkets™](https://finance.yahoo.com/healthcare/articles/molecular-diagnostics-market-grow-usd-144500704.html) — Aug 19, 2026
- [Tracking Al Gore's Generation Investment Management Portfolio - Q2 2026 Update](https://seekingalpha.com/article/4938038-al-gore-generation-investment-management-portfolio-q2-2026-update) — Aug 18, 2026
- [The 5 Safest Vanguard Funds to Own in a Volatile Market](https://www.kiplinger.com/slideshow/investing/t041-s001-the-6-best-vanguard-funds-to-own-in-a-bear-market/index.html) — Aug 18, 2026
- [QDEL's 2026 Outlook Cut Deepens China and Respiratory Risk Concerns](https://finance.yahoo.com/healthcare/articles/qdels-2026-outlook-cut-deepens-180500327.html) — Aug 17, 2026
- [Is QDEL Worth Buying as China Risks Clash With Resilient Core Growth?](https://finance.yahoo.com/markets/stocks/articles/qdel-worth-buying-china-risks-175600089.html) — Aug 17, 2026
- [QDEL Rallies 31.7% in Three Months: Can the Stock Keep Climbing Higher?](https://finance.yahoo.com/markets/stocks/articles/qdel-rallies-31-7-three-174600916.html) — Aug 17, 2026
- [Research Tools & Consumables Stocks Q2 Highlights: Danaher (NYSE:DHR)](https://finance.yahoo.com/markets/stocks/articles/research-tools-consumables-stocks-q2-221300365.html) — Aug 16, 2026

## Frequently asked questions

### What is the current market sentiment for DHR?

As of Aug 23, 2026, Danaher Corporation (DHR) carries positive (+28 on a −100 to +100 scale) composite sentiment. The score fuses recent news tone, analyst recommendations, technical posture, insider and congressional activity, and market attention into a single figure. The full breakdown of each component is in the report.

### How has DHR stock been performing?

Danaher Corporation last closed at $218.85, in the upper half of its 52-week range of $160.93–$242.80.

### What is DHR's market cap and valuation?

Danaher Corporation has a market capitalization of about $153.85B, a trailing P/E of 39.1, a dividend yield of 0.73%.

### What sector is DHR in, and who are its competitors?

Danaher Corporation operates in the Healthcare sector, specifically Diagnostics & Research. Comparable companies include TMO, A, IQV, WAT, ILMN.

### Where can I find a full analysis of DHR?

The full DHR report covers the bull and bear cases, technical signals with entry, stop and target levels, complete financial statements, earnings history, insider and congressional trades, and the conditions that would invalidate the thesis. It requires a free account.

## Important information

This page is generated from public market and company information. Data can be delayed, incomplete, or wrong. It is research and analysis, not financial advice.

- [Methodology](https://synoptiv.com/methodology)
- [Disclosures](https://synoptiv.com/disclosures)
- [Full report](https://synoptiv.com/stock/DHR/v/1) (account and access required)